A Registry Study on HIV-related Lymphoma

  • STATUS
    Recruiting
  • End date
    Aug 31, 2029
  • participants needed
    300
  • sponsor
    Rotkreuzklinikum München gGmbH
Updated on 22 March 2022

Summary

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

Description

To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.

Details
Condition AIDS Related Lymphoma, HIV Related Lymphoma
Clinical Study IdentifierNCT05231135
SponsorRotkreuzklinikum München gGmbH
Last Modified on22 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
HIV-infection at time of lymphoma diagnosis
Lymphoma diagnosis since 01.01.2010
Adult patients ≥ 18 years
Written informed consent

Exclusion Criteria

HIV-diagnosis > 3 months after the diagnosis of malignant lymphoma
Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note